• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form RW filed by Azitra Inc

    10/14/25 8:30:20 AM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AZTR alert in real time by email
    RW 1 formrw.htm RW

     

    October 14, 2025

     

    VIA EDGAR

     

    U.S. Securities and Exchange Commission

    Division of Corporation Finance

    100 F Street, N.E.

    Washington, D.C. 20549

     

    Re: Azitra, Inc.
      Registration Statement on Form S-1
      File No. 333-289961

     

    Ladies and Gentlemen:

     

    On August 29, 2025, Azitra, Inc., a Delaware corporation (the “Company”), filed a Registration Statement on Form S-1 (File No. 333-289961) (the “Registration Statement”), with the Securities and Exchange Commission (the “Commission”). In accordance with Rule 477 under the Securities Act of 1933, as amended (the “Securities Act”), the Company hereby respectfully makes this application to withdraw the Registration Statement, together with all exhibits thereto. The Company submits this request for withdrawal because the Company has elected not to pursue the sale of securities pursuant to the Registration Statement at this time.

     

    No securities have been issued or sold under the Registration Statement. The Registration Statement has not been declared effective by the Commission.

     

    The Company respectfully requests that the Commission issue an order granting withdrawal of the Registration Statement. The Company further requests that all fees paid to the Commission in connection with the filing of the Registration Statement be credited for future use in accordance with Rule 457(p) of the Securities Act.

     

    Your assistance in this matter is greatly appreciated. If you have any questions regarding this application for withdrawal, please contact Faith Charles, outside counsel for the Company, at (212) 908-3905.

     

      Very truly yours,
         
      AZITRA, INC.
         
      By: /s/ Francisco Salva
      Name: Francisco Salva
      Title: Chief Executive Officer

     

     

     

    Get the next $AZTR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AZTR

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $AZTR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Azitra, Inc. Announces Q3 2025 Results and Provides Business Updates

    BRANFORD, Conn., Nov. 12, 2025 /PRNewswire/ -- Azitra, Inc. ("Azitra") (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the quarter ended September 30, 2025, and provided a business update. Q3 2025 and Recent Business Highlights Dosed first patient in Phase 1/2 trial for ATR-04 program targeting oncology patients with EGFRi-associated rash in August 2025Presented positive preclinical data at BIO-Europe® for ATR-01 program, targeting the treatment of ichthyosis vulg

    11/12/25 5:15:00 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Azitra, Inc. Addresses False Report Regarding Sale of Securities

    BRANFORD, Conn., Nov. 7, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that it has come to the Company's attention that a report has been circulated claiming that the Company priced a $44 million registered direct offering. This report is false and should not be relied upon. Azitra urges investors, stakeholders, and the public to rely only on information formally issued by the Company through its official channels. The Company is taking steps to ide

    11/7/25 6:00:00 AM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Azitra, Inc. Announces Positive Preclinical Data for ATR-01 Program, Designed to Treat Ichthyosis Vulgaris

    ATR-01, which uses a filaggrin-secreting strain of S. epidermidis, is in preclinical development for ichthyosis vulgaris Preclinical data show production of active, functional filaggrin delivered through human stratum corneum and repair of damaged model skin Further details to be presented in virtual presentation at BIO-Europe ® BRANFORD, Conn., Oct. 20, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced that Cofounder and Chief Operating Officer, Travis Whitfill, PhD, MPH, will present positive preclinical progress for its ATR-01 program, targeting the treatment of ic

    10/20/25 8:02:00 AM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZTR
    SEC Filings

    View All

    Azitra Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Azitra, Inc. (0001701478) (Filer)

    11/12/25 5:01:17 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Azitra Inc

    10-Q - Azitra, Inc. (0001701478) (Filer)

    11/12/25 5:00:35 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form RW filed by Azitra Inc

    RW - Azitra, Inc. (0001701478) (Filer)

    10/14/25 8:30:20 AM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZTR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Staskey Norm bought $10,034 worth of shares (47,600 units at $0.21), increasing direct ownership by 1,360% to 51,100 units (SEC Form 4)

    4 - Azitra, Inc. (0001701478) (Issuer)

    4/1/24 9:51:59 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZTR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Staskey Norm bought $10,034 worth of shares (47,600 units at $0.21), increasing direct ownership by 1,360% to 51,100 units (SEC Form 4)

    4 - Azitra, Inc. (0001701478) (Issuer)

    4/1/24 9:51:59 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZTR
    Financials

    Live finance-specific insights

    View All

    Azitra, Inc. Announces Full Year 2024 Financial Results and Provides Business Updates

    BRANFORD, Conn., Feb. 20, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the full year ended December 31, 2024, and provided a business update. FY 2024 and Recent Business Highlights Initiated a Phase 1b clinical trial investigating ATR-12 in adult Netherton syndrome patients; Initial safety data from first set of Netherton syndrome patients expected in the first half of 2025 with topline data from the Phase 1b trial by year-end 2025Received clearance from the U.S. Food and Drug Administration (FDA) for a first-in-human Phase 1/2 clinical stu

    2/24/25 8:30:00 AM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Azitra, Inc. Announces Q3 2024 Financial Results and Provides Business Updates

    BRANFORD, Conn., Nov. 12, 2024 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the three months ended September 30, 2024 and provided a business update. Q3 2024 and Recent Business Highlights: Completed a follow-on offering of $10 million in gross proceedsDosed first Netherton syndrome patient with ATR-12Submitted an IND to the FDA and received IND clearance for ATR-04 to treat skin rash from EGFR inhibitorsReceived Fast Track designat

    11/12/24 5:05:00 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Azitra, Inc. Announces Q2 2024 Financial Results and Provides Business Updates

    Azitra, Inc. (NYSE:AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the three months ended June 30, 2024, and provided a business update. Q2 2024 and Recent Business Highlights Completed a follow-on offering of $10 million in gross proceeds expected to provide cash runway into 2025. With the recent financing, the company anticipates announcing multiple clinical milestones Strengthened global intellectual property portfolio with newly granted and allowed patents Exhibited positive preclinical data from ATR-04 at the Society of Investigative Dermatology Annual Meeting Pres

    8/12/24 6:23:00 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZTR
    Leadership Updates

    Live Leadership Updates

    View All

    Azitra, Inc. Appoints Travis Whitfill as Chief Operating Officer

    BRANFORD, Conn., July 11, 2023 /PRNewswire/ -- Azitra, Inc. (NYSE:AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the appointment of Travis Whitfill as Chief Operating Officer. Mr. Whitfill is the cofounder of Azitra and joins from Bios Partners, a venture capital firm focused on investing in early-stage biopharmaceutical companies. "We are delighted to welcome Travis back to Azitra full time, after his tenure of nearly ten years in biotech venture capital," said Francisco Salva, President and CEO of Azitra. "Travis brings a wealth of knowledge in biotech, synthetic biology, and drug development. He will

    7/11/23 4:05:00 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZTR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Azitra Inc

    SC 13G/A - Azitra, Inc. (0001701478) (Subject)

    11/14/24 12:56:51 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Azitra Inc

    SC 13G/A - Azitra, Inc. (0001701478) (Subject)

    11/14/24 12:18:21 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Azitra Inc

    SC 13G/A - Azitra, Inc. (0001701478) (Subject)

    11/6/24 4:35:43 PM ET
    $AZTR
    Biotechnology: Pharmaceutical Preparations
    Health Care